Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Two Indianapolis benefits consulting firms have finalized their merger, the companies announced this morning. Terms of the
deal between Benefit Associates Inc. and Benefit Consultants Inc., in the works since March, were not disclosed.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Once again, Indianapolis-based Eli Lilly and Co. is running in the lead pack in dollars spent to bend ears on Capitol Hill. And that was even before the health care reform debate got rolling.
The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.
Private equity firms have a reputation as ruthless acquirers. They slash fat and jettison sluggish product lines, all in a quest to wring out higher profits and grow the parts of the business with the most potential. For Indianapolis-based Dow AgroSciences—or at least for its 1,200 local employees—a buyer like that would be a godsend. […]
A new communications post at Eli Lilly gives former mayor Bart Peterson an opportunity to meld his experiences in the public
and private sectors.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
The CEO of the Wishard Foundation resigned last month, prompting the fund-raising arm of Wishard Health Services to tap consulting
firm Johnson Grossnickle & Associates for a replacement.
Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
Express Scripts Inc. has cleared an
antitrust review for its planned purchase of Indianapolis-based WellPoint
Inc.’s pharmacy benefits management business, bringing the $4.7 billion deal
closer to completion.
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
In a state steeped in advanced research that spawns biomedical companies by the dozen, Apricity LLC is preposterously low-tech,
given that its latest product is nothing more than a warm blanket.
The anchor tenant in the Binford Medical-Professional Office Complex at the corner of 65th Street and Binford Boulevard has closed temporarily, citing a lack of other tenants in the high-profile medical building. The shut-down is the latest in a string of setbacks for what was to have been a five-building, $29 million development. The Binford […]
Financial reports trickling in from Indianapolis’ major hospitals show why the city’s health care building boom ground to
a near halt this year. It ran into a wall of investment losses.
The cost of nursing home care in Indianapolis is rising faster than in the rest of the country, according to an annual survey
of long-term-care costs by Virginia-based Genworth Financial.
Specialist physicians, who have traditionally been fiercely independent, are more and more coming on as employees of hospitals.
An activist shareholder vying to become a director of Conseco Inc. says the insurance company’s board "completely misjudged"
the risks it faced when it emerged from bankruptcy in 2003 and hasn’t recovered since. Now an independent shareholder advisory firm is siding with him.
Ma quande lingues coalesce, t va semblar un simplificat Angles, quam un skeptic Cambridge amico dit me que Occidental es.
